Editorial Videos

In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.

In this Applied Clinical Trials video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, talks about the role of technology in addressing the data gap in women's health research and encourages women interested in healthcare to go for it.

In this Applied Clinical Trials video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, talks about the program's creation and their most successful strategies for encouraging the inclusion of women of childbearing age in clinical trials.

In this Applied Clinical Trials video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, discusses the specific challenges women with chronic illnesses face when it comes to participating in clinical trials.

In this Applied Clinical Trials video interview, Julia Lakeland, Chief Product Officer, uMotif, talks about the ethical considerations that need to be addressed when implementing new technologies for collecting and analyzing patient data in clinical trials, while ensuring patient privacy.

In this Applied Clinical Trials video interview, Julia Lakeland, Chief Product Officer, uMotif, discusses new technologies that can help personalize the clinical trial experience for diverse patient populations.

In this Applied Clinical Trials video interview, Julia Lakeland, Chief Product Officer, uMotif, discusses the development of new technologies helping to foster trust and informed decision-making throughout the clinical trial process.

In this Applied Clinical Trials video interview, Julia Lakeland, Chief Product Officer, uMotif, discusses what kinds of technologies can be developed to improve patient engagement while still maintaining data integrity.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, speak on what they think the future looks like when it comes to streamlining and improving the clinical trial imaging landscape.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, discuss adapting to the specific needs and considerations of trials with cardiac, neuro, and pulmonary specialties.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, talk about ways their company has improved efficiency and accuracy in clinical trials for clients such as NCI designated cancer centers.

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, provide commentary on current obstacles associated with clinical trials and how their company is addressing them.

In an interview with ACT Editor Andy Studna, Gadi Saarony, CEO, Advarra, offers his thoughts on the status of the pharmaceutical industry improving diversity in clinical trials.

Christian Olsen, VP, Industry Principal of Biologics at Dotmatics, discusses how artificial intelligence along with other technologies are being used to shorten the drug discovery funnel and reduce research costs.

In an interview with ACT editor Andy Studna at SCOPE, Corrigan discusses what YPrime is doing to address challenges in clinical trials and results from the company's recently released eCOA report.

In an interview with ACT editor Andy Studna at SCOPE, Deyle, VP & GM, Clinical Research, Flatiron Health discusses real-world evidence in clinical trials.

In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.

In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.

In an interview with ACT editor Andy Studna at SCOPE, Morahan, senior director, clinical data analytics, IQVIA Technologies discusses how AI can advance trial execution and what stakeholders should be keeping top of mind when choosing technology vendors.

In an interview with ACT Editor Andy Studna, Jim Reilly, VP, R&D Strategies, Veeva Systems, discusses improving collaborations with research sites and provides an outlook of how the new year looks for clinical trials.

In an interview with ACT Associate Editor Don Tracy, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, provides her thoughts on the success of the trial.

In an interview with ACT editor Andy Studna, Jim Reilly, VP, R&D Strategy, Veeva Systems, discusses ways stakeholders can select the best solutions available in clinical trials.

In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses the Summit for Clinical Ops Executives (SCOPE) conferences in Europe and the US.

In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses what ClinEco is and how the need to create it came about.

Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene discusses their new study 'Reshaping Pharmacovigilance in the Age of AI'

In an interview with ACT editor, Andy Studna, Hesterlee, Chief Research Officer at the Muscular Dystrophy Association discusses a new therapy for Duchenne Muscular Dystrophy, Vamorolone, and what sets it apart from other therapies in the market.

New pre-competitive, disease-agnostic Consortium hopes to optimize advocacy group-industry collaboration to ultimately accelerate the pace of medicines development.

Slope.io CEO Rust Felix Discusses Phase I/II Oncology Sample Management Using Logistical Workflows